Immutep Enters Into Second Clinical Trial Collaboration Agreement With Merck KGaA, Darmstadt, Germany, And Pfizer For New Combination Study Of Its First-In-Class Lag-3 Candidate, Eftilagimod Alpha, And Avelumab To Treat Urothelial Cancer

Follow us on Google News:
 Immutep Enters Into Second Clinical Trial Collaboration Agreement With Merck KGaA, Darmstadt, Germany, And Pfizer For New Combination Study Of Its First-In-Class Lag-3 Candidate, Eftilagimod Alpha, And Avelumab To Treat Urothelial Cancer
Image source: ©2022 Kalkine Media®

Nov 29 (Reuters) - Immutep Ltd:


* IMMUTEP ENTERS INTO SECOND CLINICAL TRIAL COLLABORATION AGREEMENT WITH MERCK KGAA, DARMSTADT, GERMANY, AND PFIZER FOR NEW COMBINATION STUDY OF ITS FIRST-IN-CLASS LAG-3 CANDIDATE, EFTILAGIMOD ALPHA, AND AVELUMAB TO TREAT UROTHELIAL CANCER

* IMMUTEP ENTERS INTO SECOND CLINICAL TRIAL COLLABORATION AGREEMENT WITH MERCK KGAA, DARMSTADT, GERMANY, AND PFIZER FOR NEW COMBINATION STUDY OF ITS FIRST-IN-CLASS LAG-3 CANDIDATE, EFTILAGIMOD ALPHA, AND AVELUMAB TO TREAT UROTHELIAL CANCER

* IMMUTEP LTD - FIRST PATIENT IS EXPECTED TO BE ENROLLED AND DOSED IN H1 OF CALENDAR YEAR 2023

* IMMUTEP LTD - UNDER AGREEMENT, IMMUTEP AND MERCK KGAA, DARMSTADT, GERMANY WILL JOINTLY FUND INSIGHT-005 STUDY Source text for Eikon: Further company coverage:

Disclaimer

The above content is directly sourced from Reuters under a contractual arrangement. The content is being provided as a convenience and for informational purposes only; and does not constitute an endorsement or approval by Kalkine Media of any of the products, services, or opinions of the organization or individual. The user is apprised that Kalkine Media bears no responsibility for the accuracy, legality, or content of Reuters, any external sites, or for that of subsequent links. The user is requested to contact Reuters directly for answers to questions regarding the content. Please note that Kalkine Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

Featured Articles